SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lincoln Pharmaceuticals slips after Tanzania bans chloramphenicol sodium succinate injection

18 Jan 2016 Evaluate

Lincoln Pharmaceuticals is currently trading at Rs. 179.20, down by 44.70 points or 19.96% from its previous closing of Rs. 223.90 on the BSE.

The scrip opened at Rs. 221.00 and has touched a high and low of Rs. 223.00 and Rs. 179.20 respectively. So far 11,20,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 304.80 on 06-Jan-2016 and a 52 week low of Rs. 72.75 on 09-Mar-2015.

Last one week high and low of the scrip stood at Rs. 292.50 and Rs. 179.20 respectively. The current market cap of the company is Rs. 292.29 crore.

The promoters holding in the company stood at 36.11% while Institutions and Non-Institutions held 0.93% and 62.96% respectively.

Lincoln Pharmaceuticals’ highest selling chloramphenicol sodium succinate injection has been banned in Tanzania and the company's registration has also been cancelled there. Chloramphenicol Sodium Succinate Injection is an antibiotic used to treat serious bacterial infections.

Lincoln Pharmaceuticals is a company is based at Ahmedabad and engaged in Manufacturing and Export of Pharmaceuticals formulations under various Therapeutic product group, plant duly complied with WHO-GMP guidelines. The Company is exporting more than 45 countries along with Domestic market in more than 20 states in India.



Lincoln Pharma Share Price

586.60 -5.80 (-0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×